vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
Published 2 years ago • 740 plays • Length 3:03Download video MP4
Download video MP3
Similar videos
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
10:20
psmafore results: [177lu]lu-psma-617 in taxane-naive patients with mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
6:22
prostate cancer treatment in germany - lutetium-177 psma | stories from our patients
-
11:01
lutetium-177: psma guided treatment | #prostatecancer | #markscholzmd | #pcri
-
22:27
prostate cancer treatment in germany - lutetium-177 psma | dr. med. stefan dresel | ask the doctor
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
1:09
psma imaging pre- and post-177lu-psma-617 treatment in mcrpc
-
3:25
highlights on lu-psma-617 in taxane-naive patients with mcrpc: the psmafore study
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
3:17
safety and efficacy of 177lu-psma-617
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
0:54
predicting 177lu-psma-617 in men with prostate cancer with nomograms
-
5:06
psmaddition: 177lu-psma-617 plus soc vs. soc alone in metastatic hormone-sensitive prostate cancer
-
1:38
177lu-psma i&t for patients with psma-positive mcrpc